Home  »  Companies   »  KRON Stock: Kronos Bio Inc. (NASDAQ:KRON) Is Still...

KRON Stock: Kronos Bio Inc. (NASDAQ:KRON) Is Still Worth a Bite

Kronos Bio Inc. (NASDAQ:KRON) Relative Strength Index (RSI) is 44.62, with weekly volatility at 5.74% and ATR at 1.62. The KRON stock’s 52-week price range has touched low of $19.60 and a $39.60 high. Intraday shares traded counted 0.61 million, which was -137.43% lower than its 30-day average trading volume of 256.58K. Its shares traded lower over the last trading session, losing -0.75% on 06/17/21. The shares fell to a low of $24.58 before closing at $25.10. KRON’s previous close was $25.29 while the outstanding shares total 54.15M.

Investors have identified the Biotechnology company Kronos Bio Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.44 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.

Kronos Bio Inc. (KRON) Fundamentals that are to be considered.

When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 405.27 million total, with 11.29 million as their total liabilities.

KRON were able to record -20.5 million as free cash flow during the 09/01/2021 quarter of the year, this saw their quarterly net cash flow reduce by -106.56 million. In cash movements, the company had a total of -19.0 million as operating cash flow.

Having a look at the company’s valuation, the company is expected to record -2.60 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on KRON sounds very interesting.

Is the stock of KRON attractive?

In related news, Director, De Backer Marianne bought 600 shares of the company’s stock in a transaction that recorded on May 28. The purchase was performed at an average price of 25.01, for a total value of 15,006. As the purchase deal closes, the Director, Loven Jakob now sold 21,551 shares of the company’s stock, valued at 433,185. Also, Director, Loven Jakob sold 14,004 shares of the company’s stock in a deal that was recorded on Apr 19. The shares were cost at an average price of 20.59 per share, with a total market value of 288,278. Following this completion of disposal, the Director, Loven Jakob now holds 33,162 shares of the company’s stock, valued at 696,762. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.40%.

4 out of 4 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Kronos Bio Inc.. 0 analysts has assigned a Sell rating on the KRON stock. The 12-month mean consensus price target for the company’s shares has been set at $44.33.

Leave a Comment

Your email address will not be published.